NCT06607185 2026-03-13
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
Eli Lilly and Company
University of Southern California
Trishula Therapeutics, Inc.
Purple Biotech Ltd.
Actuate Therapeutics Inc.